07 Jan 2001

Betnesol®-V Lotio (Betnesol®-V Lotio 0,1%) - Deutschland

Updated: 07 Jan 2001

Betnesol®-V Lotio 0,1%; -mite Creme 0,05% | -Creme 0,1%; -mite Salbe 0,05% | -Salbe 0,1%

Hauterkrankungen, die auf lokale Corticoidbehdlg. ansprechen.

Betnesol®-V Lotio Description, Presentation and Dosage

Betnesol®-V Lotio Description

Betnesol®-V Lotio Drug Class Description


Betnesol®-V Lotio Drug Description

1 g enth.: Betamethason-17-valerat 1,22 mg (entspr. 1 mg Betamethason).

Betnesol®-V Lotio Generic Name

Betnesol®-V Lotio 0,1%

Betnesol®-V Lotio Presentation

Betnesol®-V Lotio Presentation

Betnesol®-V Lotio 0,1%; -mite Creme 0,05%/-Creme 0,1%; -mite Salbe 0,05%/-Salbe 0,1%

Betnesol®-V Lotio Manufacturer

Glaxo Wellcome/Cascan

Related Learning Zones

COPD Knowledge Centre

COPD Knowledge Centre

The COPD Knowledge Centre has been designed to provide healthcare professionals with free access to educational materials and disease awareness information. This includes information on the epidemiology, pathophysiology and symptoms of COPD and the latest guidelines for the diagnosis, treatment and management of the disease.

COPD-specific resources such as videosguidelinesinfographics, materials for your patients, upcoming events, useful websites and symposium videos and materials from ATS 2015 are available free of charge.

LAL-D Knowledge Centre

LAL-D Knowledge Centre

The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.

Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH

Betnesol®-V Lotio Dosage

Betnesol®-V Lotio Adult Dosage

Cetylstearylalkohol, Methyl-4-hydroxybenzoat, Diethylenglycolmonostearat, Cetomacrogol 1000, dickfl. Paraffin, Glycerol, Isopropylalkohol.

Betnesol®-V Lotio Child Dosage

Betnesol®-V mite Creme 0,05%/-Creme 0,1%
Zus.: 1 g enth.: Betamethason-17-valerat 0,61 mg/1,22 mg (entspr. 0,5 mg/1 mg Betamethason).
Weit. Bestandteile: Chlorocresol, Cetomacrogol 1000, Cetylstearylalkohol, weißes Vaselin, dickflüssiges Paraffin.

Betnesol®-V mite Salbe 0,05%/-Salbe 0,1%
Zus.: 1 g enth.: Betamethason-17-valerat 0,61 mg/1,22 mg (entspr. 0,5 mg/1 mg Betamethason).
Weit. Bestandteile: Dickflüssiges Paraffin, Weißes Vaselin.

Betnesol®-V Lotio Precautions, Reactions and Contraindications

Betnesol®-V Lotio Special Precautions

Betnesol®-V Lotio Special Precautions

G 12, Z 3. Anwendung am Augenlid, Akne, Pruritus anogenitalis, Virusinfektionen, Säuglinge

Related Drugs - Dermatology

Back to top